M. Grier Eliasek, co-founder, president and COO of Prospect Capital Corporation (NASDAQ: PSEC), offered insight into the company's success, including 12 percent dividend yield for shareholders, in an exclusive interview on Benzinga's #PreMarket Prep morning show.
2014 marks Prospect Capital's tenth anniversary as a public company. After 10 years of being publicly traded, they've grown their market capital from ��100 million a decade ago to about $3.5 billion today.��
Eliasek said that despite high dividend yields, they've actually ��nder-distributed��relative to their income, making 12 percent easy to sustain with a ��ignificant storehouse of value of undistributed earnings.��They've declared monthly dividends moving forward all the way through to September, offering shareholders a significant amount of yield visibility.
Top Computer Hardware Companies To Invest In Right Now: Ishares Trust Dow Jones United States Real Estate (IYR)
iShares Dow Jones U.S. Real Estate Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Real Estate Index (the Index). The Index measures the performance of the real estate sector of the United States equity market.
The Index includes companies in sub sectors, such as real estate holding and development, and real estate investment trusts (REITs). The Fund uses a representative sampling strategy in seeking to track the Index that collectively has an investment profile similar to the Index.
Advisors' Opinion:- [By Markos Kaminis]
As the SPDR S&P 500 (SPY) has gained 18.1% this year, Annaly Capital shares sank approximately 17.6%; American Capital Agency and Two Harbors are down 22% and 12%, respectively. The whole real estate stock sector has been under pressure, as evidenced by the iShares US Real Estate (IYR) drop of 1.3% year-to-date. Despite a steadily improving actual real estate market, the mREIT group has faced criticism about what damage could ensue to held asset portfolio values in a rapidly rising rate environment. Also, the mortgage REITs' abilities to manage their businesses would become complicated by a rising cost of borrowing matched against longer duration income streams at low relative yields. Reduced dividends result from less income, and lower security values are priced in.
Hot High Dividend Stocks To Buy For 2014: CombiMatrix Corporation(CBMX)
CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the fields of genetic analysis and molecular diagnostics in the United States. The company, through its wholly owned subsidiary, CombiMatrix Diagnostics, operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, and other laboratories in two primary areas, including prenatal and postnatal developmental disorders, and oncology. It offers a suite of developmental disorder array tests on the prenatal and postnatal application of array-comparative genomic hybridization in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company also provides DNAarray?Heme Profile test to address various common hematological malignancies, including chronic lymphocytic leukemia; DNAarray?HER2 PRO test for breast cancer; and DNAarray?Tumor Profile test for the analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. In addition, it focuses on developing a series of drug compounds to address various oncology-related diseases. CombiMatrix Corporation was founded in 1995 and is based in Irvine, California.
Advisors' Opinion:- [By Bryan Murphy]
Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.
- [By Roberto Pedone]
One stock that's starting to trend within range of triggering a near-term breakout trade is CombiMatrix (CBMX), which operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of prenatal and postnatal development disorders, and hematology/oncology genomics. This stock hasn't done much over the last three months, with shares up by just 1.4%.
If you take a look at the chart for CombiMatrix, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $2.14 to its recent high of $2.90 a share. During that move, shares of CBMX have been making mostly higher lows and higher highs, which is bullish technical price action. That uptrend has now pushed shares of CBMX within range of triggering a near-term breakout trade.
Traders should now look for long-biased trades in CBMX if it manages to break out above some near-term overhead resistance levels at $2.90 to $2.92 a share, and then once it clears its 200-day moving average at $2.96 to more near-term overhead resistance at $3.20 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 823,656 shares. If that breakout triggers soon, then CBMX will set up to re-test or possibly take out its next major overhead resistance levels at $3.70 to $4.44 a share.
Traders can look to buy CBMX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at $2.57 a share or just below more support at $2.20 to $2.14 a share. One can also buy CBMX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Wallace Witkowski]
Also, shares of Combimatrix Corp. (CBMX) rose 7.5% to $2.73 in moderate volume late Friday following a Securities and Exchange Commission filing showing Longwood Capital Partners acquired a 5.1% stake in the microcap molecular diagnostics company.
Hot High Dividend Stocks To Buy For 2014: Nationstar Mortgage Holdings Inc (NSM)
Nationstar Mortgage Holdings Inc. is a non-bank residential mortgage servicer with a range of services across the residential mortgage product spectrum. As of December 31, 2011, the Company serviced over 645,000 residential mortgage loans. The Company�� clients include national and regional banks, government organizations, securitization trusts, private investment funds and other owners of residential mortgage loans and securities. It is a partner of financial organizations, including government-sponsored enterprises (GSEs) and other regulated institutions. The Company is a licensed servicer in all 50 states. In addition to its core servicing business, the Company has a fully integrated loan originations platform and suite of adjacent businesses.
Nationstar offers clients a range of services. The Company combines its mortgage servicing with a fully integrated loan originations platform. Nationstar offers clients a diversified array of residential mortgage services: Servicing, Originations and Other Related Services.
Servicing
The Company offers mortgage investors two primary ways to partner. A portion of its portfolio consists of owned mortgage servicing rights (MSRs). In this arrangement, the Company owns the right to collect the principal and interest due from a mortgage borrower, as well as manage the title and property insurance escrow of the collateral on behalf of mortgage investors in exchange for a monthly fee proportional to the unpaid principle balance (UPB) of the mortgage. The Company acquires MSRs either through its own origination of mortgages or by acquiring these rights from other MSR owners or the mortgage investor. It subservices multiple portfolios for federal agencies, Government Sponsored Enterprises (GSEs) and large banks. For its subservicing clients, the Company is organized to serve its clients with an Investor Collections Professional and Senior Portfolio Manager(s) assigned to each portfolio.
Originations
The! Company offers a fully integrated loan origination platform. It also operates a wholesale origination channel capable of purchasing loans primarily from Financial Institutions operating as a broker.
Other Related Services
The Company offers a full suite of additional residential mortgage services to complement its servicing business and supporting originations platform. These businesses offer a range of ancillary services, including providing services for delinquent loans, managing loans in the foreclosure/real estate owned (REO) process and providing title insurance agency, loan settlement and valuation services on newly originated and re-originated loans. Nationstar is a part owner in NREIS, which is a provider of residential and commercial mortgage and real estate solutions in the United States. Their services include title insurance and property reports; real estate appraisals and alternative valuation products; settlement and closing services; commercial real estate services; default and property preservation services, and flood and tax certifications.
Advisors' Opinion:- [By Monica Wolfe]
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The ��eal Time Picks��reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases and buys in Real Time activity from Kyle Bass (Trades, Portfolio) and Paul Singer (Trades, Portfolio).Kyle Bass (Trades, Portfolio) Over the past week Kyle Bass (Trades, Portfolio) made a notable increase in to Nationstar Mortgage Holdings (NSM). The guru added a total of 3,673,972 shares of the company�� stock. He bought these shares at an average price of $31.27 per share, and since then the price per share has gone up about 5% to $32.80 per share.Bass now holds on to 4,759,610 shares of Nationstar Mortgage holdings, representing 5.26% of the company�� shares outstanding.Bass�� historical holding history as of the close of the fourth quarter 2013:Nationstar Mortgage provides residential mortgage loan services. It services residential mortgage loans throughout the United States. Nationstar is one of the largest servicers in the US, with a residential mortgage servicing portfolio of over $391 billion in unpaid principal balance as of Dec. 31, 2013.Nationstar Mortgage�� historical revenue and net income:The company recently released its fourth quarter and full year financial results which highlighted:- 2013 GAAP EPS of $2.40 on net income of $217 million.- Ending servicing portfolio UPB of $391 billion.- 2013 servicing portfolio growth of 88%.- 2013 return on equity of 25%.- Funded volume of $24 billion in 2013.The company also recently announced that they had received a letter from Benjamin Lawsky, Superintendent of the New York Department of Financial Services, which inquires about Nat
- [By Lauren Pollock]
New Residential Investment Corp.(NRZ) and other investors agreed to buy about $3.2 billion of servicing advances from Nationstar Mortgage Holdings Inc.(NSM), part of Nationstar’s plan to reconfigure its acquisition structure. The advances relate to nonagency residential mortgage loans with an unpaid principal balance of about $58 billion. Nationstar shares rose 4.1% to $42.50 in light premarket trading.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Nationstar Mortgage Holdings (NYSE: NSM) were down 17.33 percent to $40.69 after the company reported Q3 results. Stonegate Mortgage announced its plans to acquire Nationstar's wholesale lending channel.
Hot High Dividend Stocks To Buy For 2014: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Inovio Pharmaceuticals (NYSE: INO) were down on Friday's session, falling 13.28 percent to $2.488 despite seemingly little news on the company. - [By Sean Williams]
No fairytale ending
Fairytale endings work great in the movies, but you rarely see them come to fruition in the real world. Small-cap biopharmaceutical Inovio Pharmaceuticals (NYSEMKT: INO ) has seen shares nearly triple since April on the heels of multiple intriguing studies, but will the glass slipper fit over the long term?
Hot High Dividend Stocks To Buy For 2014: Regus plc (RGV)
Regus plc is a Luxembourg-based provider of global office outsourcing services. Its primary activity and business segment is the provision of global workplace solutions. There are three parts to the Company�� business: Mature, New and Third Place. The Company�� products and services include outsourcing, workplace recovery, business lounges, businessworld, meeting rooms, video communications, offices and virtual offices. It offers bespoke packages for starting a business, home based business, mall and medium business, international business and corporate workspace solutions. It has some 1,203 locations across 550 cities in 94 countries serving more than a million customers. Its principal geographical segments include Americas; Europe, Middle East and Africa; Asia Pacific; and the United Kingdom. In June 2013, Regus plc announced that it has launched its business centre in Nepal. Advisors' Opinion:- [By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.
No comments:
Post a Comment